Cardiovascular Business presents: The most popular stories of 2020

Cardiac involvement and myocardial inflammation are common in recovered COVID-19 patients, according to a new study published in JAMA Cardiology.

Hypertensive patients may be at a greater risk of dying from COVID-19, the viral disease stemming from the world’s largest coronavirus outbreak to date, according to Bloomberg News.

In addition to these latest findings, a NIH-backed panel is now specifically recommending against the combination of hydroxychloroquine and azithromycin for treating COVID-19 patients.

Hydroxychloroquine was once just an ordinary antimalarial medication—and then 2020 and COVID-19 happened. So how did we get here? 

The FDA has added at least three additional items to its growing roster of heartburn drug recalls.

A 50-year-old cardiologist has died from complications related to COVID-19.

Just days before the American College of Cardiology canceled its annual scientific sessions for the first time in the meeting’s 69-year history, it released a set of guidelines for cardiology care teams dealing with the COVID-19 outbreak.

The role of ACE inhibitors and ARBs in the treatment of COVID-19 has been a key topic for researchers since the pandemic began. This latest research represents a significant update for clinicians. 

New legislation has been introduced that would forgive student loan debt for frontline healthcare workers who have provided patient care during the ongoing COVID-19 pandemic.

The role of ACE inhibitors and ARBs in the treatment of COVID-19 has been a key topic for researchers since the pandemic began. This latest research represents a significant update for clinicians.